AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

Giovanni Martinelli, Armando Santoro, Carlo Gambacorti-Passerini, Susana Vives Polo, Scott R. Solomon, Sudipto Mukherjee, Ewa Lech-Maranda, Moshe Yair Levy, Agnieszka Wierzbowska, María Calbacho-Robles, Giovanni Marconi, Maria Benedetta Giannini, Isabel Cano, Laura Torres Miñana, Evelyn Acuña-Cruz, Noemi Angelosanto, Tariq I. Mughal, Antonio Galleu, Simona Blotta, Farhad RavandiPau Montesinos

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences